Association Between EGFR Mutation Status and Out-of-field Recurrence in Locally Advanced Unresectable Non-small Cell Lung Cancer Treated With Chemoradiotherapy and Durvalumab Consolidation.

Endo M, Fukuda Y, Nakagawa M, Ogawa K, Nakamura M, Irie D, Takahashi S, Kawahara M, Akahane K, Maemondo M, Yamaguchi Y, Mori H, Shirai K

Open source

DOI
10.21873/anticanres.18361
Published
2026 Sep
Container
Anticancer research
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.21873/anticanres.18361,
  title = {Association Between EGFR Mutation Status and Out-of-field Recurrence in Locally Advanced Unresectable Non-small Cell Lung Cancer Treated With Chemoradiotherapy and Durvalumab Consolidation.},
  author = {Endo M and Fukuda Y and Nakagawa M and Ogawa K and Nakamura M and Irie D and Takahashi S and Kawahara M and Akahane K and Maemondo M and Yamaguchi Y and Mori H and Shirai K},
  year = {2026},
  journal = {Anticancer research},
  doi = {10.21873/anticanres.18361},
  url = {https://doi.org/10.21873/anticanres.18361}
}

RIS

TY  - JOUR
TI  - Association Between EGFR Mutation Status and Out-of-field Recurrence in Locally Advanced Unresectable Non-small Cell Lung Cancer Treated With Chemoradiotherapy and Durvalumab Consolidation.
AU  - Endo M
AU  - Fukuda Y
AU  - Nakagawa M
AU  - Ogawa K
AU  - Nakamura M
AU  - Irie D
AU  - Takahashi S
AU  - Kawahara M
AU  - Akahane K
AU  - Maemondo M
AU  - Yamaguchi Y
AU  - Mori H
AU  - Shirai K
PY  - 2026
JO  - Anticancer research
DO  - 10.21873/anticanres.18361
UR  - https://doi.org/10.21873/anticanres.18361
ER  - 

APA

M, E., Y, F., M, N., K, O., M, N., D, I., S, T., M, K., K, A., M, M., Y, Y., H, M., & K, S. (2026). Association Between EGFR Mutation Status and Out-of-field Recurrence in Locally Advanced Unresectable Non-small Cell Lung Cancer Treated With Chemoradiotherapy and Durvalumab Consolidation.. Anticancer research. https://doi.org/10.21873/anticanres.18361

Source records